Export
The link always opens the latest version of this page.
Ask an AI about it
Open in ChatGPTA new chat that reads this entry from the site Open in ClaudeThe same, in ClaudeShare the link instead of a file, and they will always see the latest version.
Files are a snapshot of today. The live page has anything newer.
mFLUSIVA
mRNA-based influenza vaccine for seniors approved by FDA
- Category
- vaccine 1 source
mFLUSIVA is an mRNA-based influenza vaccine developed by Moderna for seniors.
The vaccine leverages mRNA platform technology, representing an alternative to traditional egg-based influenza vaccine manufacturing. A key advantage of the mRNA approach is its significantly faster production timeline: mFLUSIVA can be manufactured in 1-2 months 1, compared to 6-8 months for conventional egg-based vaccines 1. This accelerated timeline potentially enables more rapid response to emerging influenza strains and seasonal demand.
Facts 2
| Attribute | Value | Confidence | Sources | Cited |
|---|---|---|---|---|
| Vendor | Moderna | low | 1 | 1 |
| Category | vaccine | low | 1 | 1 |
Affected version 2
- production timeline 1-2 months vs egg-based 6-8 months
- approved for adults 50 and up
Platform 3
Developed by 1
Official links
Frequently mentioned together 4
Sources 3
- Moderna's mRNA flu shot earns FDA approval after rollercoaster review · Ars Technica
- FDA Approves First mRNA Flu Shot · Slashdot
- The quick guide to fall vaccines and when you should get them · Ars Technica